Cited by 401BRCA gene mutations in cancerPancreatic and Hepatic Oncology ResearchGenetic factors in colorectal cancer

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

Open access

Holter, Spring, Borgida, Ayelet, Dodd, Anna, Grant, Robert, Semotiuk, Kara, Hedley, David, Dhani, Neesha, Narod, Steven, Akbari, Mohammad, Moore, Malcolm, Gallinger, Steven·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.7401

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: The main purpose of this study was to determine the prevalence of pathogenic BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort of patients with pancreatic ductal adenocarcinoma and describe the clinical and family history characteristics. Patients and Methods: Unselected, consecutive, incident patients with pancreatic ductal adenocarcinoma were recruited at a single cancer center over a 2-year period. Participants provided blood for DNA analysis and cancer family history, and cancer treatment records were reviewed. DNA from all patients was analyzed by Sanger sequencing and multiplex ligation-dependent probe amplification for germline variants in BRCA1 and BRCA2. Results: Three hundred six patients were eligible for analysis. Pathogenic germline BRCA mutations were identified in 14 patients (4.6%; 95% CI, 2.2% to 6.9%), including 11 patients with a BRCA2 mutation and three patients with a BRCA1 mutation. Having a cancer family history that met genetic testing criteria of the National Comprehensive Cancer Network or the Ontario Ministry of Health and Long-Term Care or self-reporting as Ashkenazi Jewish was significantly associated with BRCA mutation carrier status (P = .02, P < .001, and P = .05, respectively). However, the majority of the BRCA mutation–positive patients did not actually meet these genetic testing criteria. Conclusion: Pathogenic BRCA mutations were identified in 4.6% of a large cohort of clinic-based patients. Considering the implications for family members of BRCA carriers, and possibly tailored chemotherapeutic treatment of patients, our finding has implications for broader BRCA genetic testing for patients with pancreatic ductal adenocarcinoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.7401

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer risks in BRCA2 mutation carriers.
Olsson, H. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,404
Cancer Incidence in BRCA1 mutation carriers.
Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,075
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Self-citation
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 5

Lal G, 2000, Cancer Res, 60, 409
Tersmette AC, 2001, Clin Cancer Res, 7, 738
Murphy KM, 2002, Cancer Res, 62, 3789
Goggins M, 1996, Cancer Res, 56, 5360
Levy-Lahad E, 1997, Am J Hum Genet, 60, 1059

Sorted by citations

Items 101–200 of 401

Hereditary pancreatic cancer: related syndromes and clinical perspective
Carrera, S., Sancho, A., Azkona, E., Azkuna, J., & López-Vivanco, G. (2017) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-017-0069-6 · Cited by 36
Electrochemical protein recognition based on macromolecular self-assembly of molecularly imprinted polymer: a new strategy to mimic antibody for label-free biosensing
Zhao, W., Li, B. J., Xu, S., Huang, X., Luo, J., Zhu, Y., & Liu, X. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00220k · Cited by 36
Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
Barcellini, A., Peloso, A., Pugliese, L., Vitolo, V., & Cobianchi, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s220971 · Cited by 36
Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition
Principe, D. R. (2022) · Cancers · doi:10.3390/cancers14040897 · Cited by 38
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 39
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 35
The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes
Slavin, T. P., Neuhausen, S. L., Nehoray, B., Niell‐Swiller, M., Solomon, I. B., Rybak, C., Blazer, K. R., Adamson, A. W., Yang, K., Sand, S. R., et al. (2017) · Familial Cancer · doi:10.1007/s10689-017-0019-5 · Cited by 33
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
Renouf, D. J., Hedley, D. W., Krzyzanowska, M. K., Schmuck, M., Wang, L., & Moore, M. J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3102-y · Cited by 32
Self-citation
Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer
Carnevale, J. C., & Ashworth, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6961 · Cited by 32
Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma
Askan, G., Şahin, İ. H., Chou, J. F., Yavas, A., Capanu, M., Iacobuzio–Donahue, C. A., Baştürk, O., & O'Reilly, E. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08123-w · Cited by 31
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
Verdaguer, H., Saurí, T., & Macarulla, T. M. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.15 · Cited by 32
Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma
Walker, E. J., Carnevale, J. C., Pedley, C., Blanco, A. M., Chan, S. B., Collisson, E. A., Tempero, M. A., & Ko, A. H. (2018) · Familial Cancer · doi:10.1007/s10689-018-0106-2 · Cited by 30
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Wang, Y., Park, J. Y. P., Pacis, A., Denroche, R. E., Jang, G. H., Zhang, A. X. W., Cuggia, A., Domecq, C., Monlong, J., Raitses‐Gurevich, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1439 · Cited by 29
Self-citation
A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer
Astiazarán-Symonds, E., & Goldstein, A. M. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01806-y · Cited by 34
DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer
Palacio, S., McMurry, H. S., Ali, R. A., Donenberg, T. R., Silva‐Smith, R., Wideroff, G. A., Sussman, D. A., Lima, C. M. S. R., & Hosein, P. J. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.09.12 · Cited by 29
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Marco, M. D., Rodriquenz, M. G., Centonze, F., Rapposelli, I. G., Giordano, G., Vita, F. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100032 · Cited by 29
Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities
Lee, M. S., & Pant, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321255 · Cited by 30
Reflex Testing for GermlineBRCA1,BRCA2,PALB2, andATMMutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries
Smith, A. L., Wong, C., Cuggia, A., Borgida, A., Holter, S., Hall, A., Connor, A. A., Bascuñana, C., Asselah, J., Bouganim, N., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00098 · Cited by 29
Self-citation
Recapitulating the clinical scenario of BRCA‐associated pancreatic cancer in pre‐clinical models
Golan, T., Stossel, C., Atias, D., Buzhor, E., Halperin, S., Cohen, K., Raitses‐Gurevich, M., Gorman, Y. G., Raskin, S., Yehuda, D., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31292 · Cited by 28
Self-citation
Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges
Diab, M., Azmi, A. S., Mohammad, R. M., & Philip, P. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561869 · Cited by 28
S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
Seufferlein, T. T. W., Mayerle, J. V., Böck, S., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1856-7346 · Cited by 29
Updated risk factors to inform early pancreatic cancer screening and identify high risk patients
Principe, D. R., & Rana, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.022 · Cited by 27
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
Maccaroni, E., Giampieri, R., Lenci, E., Scortichini, L., Bianchi, F., Belvederesi, L., Brugiati, C., Pagliaretta, S., Ambrosini, E., & Berardi, R. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i7.565 · Cited by 26
Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b
Mogilyansky, E., Clark, P., Quann, K., Zhou, H., Londin, E. R., Yi, J., & Rigoutsos, I. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00143 · Cited by 23
Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
Perkhofer, L., Golan, T., Cuyle, P.-J. A., Matysiak‐Budnik, T., Laethem, J. V., Macarulla, T. M., Cauchin, E., Kleger, A., Beutel, A. K., Gout, J., et al. (2021) · Cancers · doi:10.3390/cancers13174259 · Cited by 25
Pancreatic Cancer: BRCA Targeted Therapy and Beyond
Keane, F., O'Connor, C. A., Park, W., Seufferlein, T. T. W., & O'Reilly, E. M. (2023) · Cancers · doi:10.3390/cancers15112955 · Cited by 26
Changing the course of pancreatic cancer – Focus on recent translational advances
Javle, M. M., Golan, T., & Maitra, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.004 · Cited by 24
Advances in the management of pancreatic ductal adenocarcinoma
O'Kane, G. M., Ladak, F., & Gallinger, S. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.201450 · Cited by 23
Self-citation
Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53
Calheiros, J., Corbo, V., & Saraiva, L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188914 · Cited by 26
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges
Jiang, Z., Zheng, X., Li, M., & Liu, M. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1050-6 · Cited by 24
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
Orsi, G., Marco, M. D., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I. G., Garajová, I., Tortora, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100238 · Cited by 24
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 23
A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing
Paiella, S., Azzolina, D., Gregori, D., Malleo, G., Golan, T., Simeone, D. M., Davis, M., Vacca, P., Crovetto, A., Bassi, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100881 · Cited by 23
Screening for pancreatic cancer has the potential to save lives, but is it practical?
Mazer, B. L., Lee, J. W., Roberts, N. J., Chu, L. C. H., Lennon, A. M., Klein, A. P., Eshleman, J. R., Fishman, E. K., Canto, M. I., Goggins, M., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2217354 · Cited by 24
Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers
de Mestier, L., Danset, J. B., Neuzillet, C., Rebours, V., Cros, J. F., Soufir, N., & Hammel, P. R. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0269 · Cited by 23
Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona
Baraniskin, A., Laethem, J. V., Wyrwicz, L. S., Güller, U., Wasan, H. S., Matysiak‐Budnik, T., Gruenberger, T., Ducreux, M. P., Carneiro, F., Cutsem, E. V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.021 · Cited by 23
Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy
Shahda, S., Timms, K. M., Ibrahim, A., Reid, J., Cramer, H. M., Radovich, M., Ibrahim, S., Allen, B. A., & O’Neil, B. H. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00087 · Cited by 22
Evaluating susceptibility to pancreatic cancer: ASCO Clinical Practice Provisional Clinical Opinion Summary
Stoffel, E. M., McKernin, S. E., & Khorana, A. A. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00629 · Cited by 22
Characteristics of early‐onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes
Eguchi, H., Kobayashi, S., Gotoh, K., Noda, T., & Doki, Y. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12326 · Cited by 21
Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment
Peters, M. L. B., Tseng, J. F., & Miksad, R. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.006 · Cited by 21
PARP inhibition in treatment of pancreatic cancer
Hammel, P. R., Zhang, C., Matile, J., Colle, E., Hadj-Naceur, I., Gagaille, M.-P., Bouattour, M., Cros, J. F., de Mestier, L., & Lamuraglia, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1820330 · Cited by 20
Organoid‐based precision medicine in pancreatic cancer
Beutel, A. K., Ekizce, M., Ettrich, T. J., Seufferlein, T. T. W., Lindenmayer, J., Gout, J., & Kleger, A. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12701 · Cited by 21
Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing
Herreros‐Villanueva, M., Bujanda, L., Ruiz-Rebollo, L., Torremocha, R., Ramos, R., Martín, R., & Artigas, M. C. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2021.12.011 · Cited by 20
The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
Zhang, J., Li, R., & Huang, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.951019 · Cited by 19
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas
Pinto, P., Peixoto, A., Santos, C., Rocha, P., Pinto, C., Pinheiro, M., Leça, L. B., Martins, A. T., Ferreira, V., Bartosch, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161438 · Cited by 22
Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma
Peters, M. L. B., Stobie, L., Dudley, B., Karloski, E., Allen, K., Speare, V., Dolinsky, J. S., Tian, Y., DeLeonardis, K., Krejdovsky, J., et al. (2019) · Cancer · doi:10.1002/cncr.32077 · Cited by 20
Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers
Kaczor‐Urbanowicz, K. E., Cheng, J. C., King, J. C., Sedarat, A., Pandol, S. J., Farrell, J. J., Wong, D. T., & Kim, Y. H. (2020) · Pancreas · doi:10.1097/mpa.0000000000001662 · Cited by 23
Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations
Hannan, Z. M., Yu, S., Domchek, S. M., Mamtani, R., & Reiss, K. A. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa121 · Cited by 20
Advances in immunotherapy and targeted therapy for pancreatic cancer
Zhou, X., Wang, X., Yang, S., & Huang, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000074 · Cited by 19
Poly(ADP-Ribose) Polymerases
Martínez‐Bosch, N., Fernández-Zapico, M. E., Navarro, P., & Yélamos, J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.09.021 · Cited by 20
Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
Lener, M. R., Scott, R. J., Kluźniak, W., Baszuk, P., Cybulski, C., Wiechowska–Kozłowska, A., Huzarski, T., Byrski, T., Kładny, J., Pietrzak, S., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30116 · Cited by 19
Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis
Imaoka, H., Sasaki, M., Hashimoto, Y., Watanabe, K., Miyazawa, S., Shibuki, T., Mitsunaga, S., & Ikeda, M. (2021) · Diagnostics · doi:10.3390/diagnostics11071195 · Cited by 19
Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
Lellouche, L., Palmieri, L., Dermine, S., Brézault, C., Chaussade, S., & Coriat, R. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018539 · Cited by 19
Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency
Li, W., Gao, L., Yi, X., Shi, S., Huang, J., Shi, L. M., Zhou, X., Wu, L., & Ying, J. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.02.004 · Cited by 19
Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations
Peters, M. L. B., Eckel, A. L., Seguin, C. L., Davidi, B., Howard, D. H., Knudsen, A. B., & Pandharipande, P. V. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00495 · Cited by 22
A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers
Alruwaili, M., Zonneville, J., Naranjo, M. N., Serio, H., Melendy, T., Straubinger, R. M., Gillard, B. M., Foster, B. A., Rajan, P., Attwood, K. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101434 · Cited by 18
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
Cedrés, S., Felip, E., Cruz, C., de Castro, A. M. M., Pardo, N., Navarro, A., Martínez‐Martí, A., Remon, J., Zerón-Medina, J., Balmañà, J., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy012 · Cited by 18
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
Pekarek, L., Fraile‐Μartinez, O., Montero, C. G., Sáez, M. A., Barquero-Pozanco, I., del Hierro-Marlasca, L., Castro-Martinez, P. D., Romero-Bazán, A., Álvarez-Mon, M. Á., Monserrat, J., et al. (2022) · Cancers · doi:10.3390/cancers14081866 · Cited by 18
Heritable Gastrointestinal Cancer Syndromes
Stoffel, E. M. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.04.008 · Cited by 18
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
Karakasis, K., Burnier, J. V., Bowering, V. L., Oza, A. M., & Lheureux, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00119 · Cited by 18
Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies
Toss, A., Venturelli, M., Molinaro, E., Pipitone, S., Barbieri, E., Marchi, I., Tenedini, E., Artuso, L., Castellano, S., Marino, M., et al. (2019) · Cancers · doi:10.3390/cancers11020193 · Cited by 17
Pancreatic cancer pathology viewed in the light of evolution
Noë, M., Hong, S., Wood, L. D., Thompson, E. D., Roberts, N. J., Goggins, M., Klein, A. P., Eshleman, J. R., Kern, S. E., & Hruban, R. H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09953-z · Cited by 17
Inherited Pancreatic Cancer Syndromes and High-Risk Screening
Biller, L. H., Wolpin, B. M., & Goggins, M. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.002 · Cited by 19
A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene
Wong, C., Chen, F., Alirezaie, N., Wang, Y., Cuggia, A., Borgida, A., Holter, S., Lenko, T., Domecq, C., Initiative, A. D. N., et al. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008344 · Cited by 19
Self-citation
Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey
Sun, P., Li, Y., Chao, X., Li, J., Luo, R., Li, M., & He, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07481-1 · Cited by 19
Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma
Fountzilas, E., Eliades, A., Koliou, G.-A., Achilleos, A., Loizides, C., Tsangaras, K., Pectasides, D. G., Sgouros, J., Papakostas, P., Rallis, G., et al. (2021) · Cancers · doi:10.3390/cancers13020198 · Cited by 17
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Kim, J. W., Cardin, D. B., Vaishampayan, U. N., Kato, S., Grossman, S. R., Glazer, P. M., Shyr, Y., Ivy, S. P., & LoRusso, P. M. (2021) · The Oncologist · doi:10.1002/onco.13758 · Cited by 17
Advances in Hereditary Colorectal and Pancreatic Cancers
Underhill-Blazey, M. L., Germansky, K. A., & Yurgelun, M. B. B. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.017 · Cited by 17
Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
Hammel, P. R., Vitellius, C., Boisteau, É., Wisniewski, M., Colle, E., Hilmi, M., d’Engremont, C., Granier, S., Turpin, A., de Mestier, L., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937949 · Cited by 16
Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
Golesworthy, B., Wang, Y., Tanti, A., Pacis, A., Romero, J. M., Cuggia, A., Domecq, C., Bourdel, G., Denroche, R. E., Jang, G. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860767 · Cited by 16
Self-citation
Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan
Ueki, A., Yoshida, R., Kosaka, T., & Matsubayashi, H. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01153-1 · Cited by 18
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake
Golan, T., Casolino, R., Biankin, A. V., Hammel, P. R., Whitaker, K. D., Hall, M. J., & Riegert‐Johnson, D. L. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231189127 · Cited by 16
The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
Shui, L., Li, X., Peng, Y., Tian, J., Li, S., He, D., Li, A., Tian, B., Mao, L., Gao, H., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02972-6 · Cited by 16
HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study
Schott, S., Yang, R., Stöcker, S., Canzian, F., Giese, N. A., Bugert, P., Bergmann, F., Strobel, O., Hackert, T., Sohn, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18757 · Cited by 16
Coming of Age in Canada: A Study of Population-Based Genetic Testing for Breast and Ovarian Cancer
Akbari, M. R., Gojska, N. M., & Narod, S. A. (2017) · Current Oncology · doi:10.3747/co.24.3828 · Cited by 17
Self-citation
Therapeutic Targeting of Oncogene-Induced Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma
Smith, S. J., Meng, F., Lingeman, R. G., Li, C. M., Li, M., Boneh, G., Seppälä, T. T., Phan, T. X., Li, H., Burkhart, R. A., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.038 · Cited by 16
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 16
Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer
LaRose, M., Manji, G. A., & Bates, S. E. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.001 · Cited by 16
Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer
Mace, T. A., Shakya, R., Elnaggar, O., Wilson, K., Komar, H. M., Yang, J. J., Pitarresi, J. R., Young, G. S., Ostrowski, M. C., Ludwig, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6332 · Cited by 15
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing
Lee, K., Yoo, C., Kim, K., Park, K., Chang, H.-M., Kim, T. W., Lee, J., Lee, W., Lee, S. S., Park, D. H., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0497-1 · Cited by 15
Pancreatic ductal adenocarcinoma in the era of precision medicine
Zheng-Lin, B., & O'Reilly, E. M. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.01.005 · Cited by 16
Genetic cancer predisposition syndromes among older adults
Chávarri-Guerra, Y., Slavin, T. P., Longoria, O., & Weitzel, J. N. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.01.001 · Cited by 16
Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling
Ettrich, T. J., Sturm, N., Güthle, M., Hüttner, F. J., & Perkhofer, L. (2022) · Visceral Medicine · doi:10.1159/000521631 · Cited by 14
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
Teo, M. Y., & O'Reilly, E. M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.05.04 · Cited by 14
Future directions in drug development in pancreatic cancer
Lambert, A., Conroy, T., & Ducreux, M. P. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.002 · Cited by 14
BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
Park, J. H., Jo, J. H., Jang, S. I., Chung, M. J., Park, J. Y., Bang, S., Park, S. W., Song, S. Y., Lee, H. S., & Cho, J. H. (2022) · Cancers · doi:10.3390/cancers14010236 · Cited by 14
Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
Connor, A. A., & Gallinger, S. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1324296 · Cited by 14
Self-citation
Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset
Ho, J., Li, X., Zhang, L., Liang, Y., Hu, W., Yau, J. C. W., Chan, H., Gin, T., Chan, M. T. V., Tse, G., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.004 · Cited by 14
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Wang, Y., Lakoma, A., & Zogopoulos, G. (2020) · Genes · doi:10.3390/genes11091098 · Cited by 14
Germline testing for individuals with pancreatic cancer: the benefits and challenges to casting a wider net
Yurgelun, M. B. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7535 · Cited by 14
Pancreatic cancer
Roth, S., Apte, M. V., Balachandran, V. P., Biffi, G., Conroy, T., Cukierman, E., Dotan, E., Esposito, I., Grünwald, B. T., Klauß, M., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00699-6 · Cited by 19
Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review
Pantaleo, A., Forte, G., Fasano, C., Signorile, M. L., Sanese, P., Marco, K. D., Nicola, E. D., Latrofa, M., Grossi, V., Disciglio, V., et al. (2023) · Cancers · doi:10.3390/cancers16010056 · Cited by 15
Pilot study of rapid MR pancreas screening for patients with BRCA mutation
Corrias, G., Raeside, M. C., Agostini, A., Castellanos, S. H., Aramburu‐Nunez, D., Paudyal, R., Shukla‐Dave, A., Smelianskaia, O., Capanu, M., Zheng, J., et al. (2019) · European Radiology · doi:10.1007/s00330-018-5975-0 · Cited by 13
Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
Okano, N., Morizane, C., Nomura, S., Takahashi, H., Tsumura, H., Satake, H., Mizuno, N., Tsuji, K., Shioji, K., Asagi, A., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01721-x · Cited by 13
Experimental models of pancreas cancer: what has been the impact for precision medicine?
Pantazopoulou, V., Kubota, C. S., Ogawa, S., Gulay, K. C. M., Lin, X., Song, H., Weitz, J., Tiriac, H., Lowy, A. M., & Engle, D. D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191945 · Cited by 16
Persistent double strand break accumulation does not precede cell death in an Olaparib-sensitive BRCA-deficient colorectal cancer cell model
Paviolo, N. S., de la Vega, M. B., Pansa, M. F., García, I. A., Calzetta, N. L., Soria, G., & Gottifredi, V. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2019-0070 · Cited by 12
Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma
Hu, H., Zhu, Y., Pu, N., Burkhart, R. A., Burns, W. R., Laheru, D. A., Zheng, L., He, J. P., Goggins, M., & Yu, J. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.06.019 · Cited by 12
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
Al-Share, B. A., Hammad, N., & Diab, M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09948-w · Cited by 12
High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer
Nakao, Y., Nakagawa, S., Yamashita, Y., Umezaki, N., Okamoto, Y., Ogata, Y., Yasuda‐Yoshihara, N., Itoyama, R., Yusa, T., Yamashita, K., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09383-9 · Cited by 14

Authors: Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., & Gallinger, S.
Affiliations: Mount Sinai Hospital (CA)
Spring Holter, Ayelet Borgida, Robert Grant, Kara Semotiuk, and Steven Gallinger, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Anna Dodd, David Hedley, Neesha Dhani, Malcolm Moore, and Steven Gallinger, McCain Pancreatic Cancer Centre, University Health Network; and Steven Narod and Mohammad Akbari, Women's College Research Institute, Toronto, Ontario, Canada.
ORCID: Borgida, Ayelet
Dodd, Anna
Grant, Robert
Semotiuk, Kara
Hedley, David
Dhani, Neesha
Narod, Steven
Akbari, Mohammad
Moore, Malcolm
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-10-01
Volume: 33
Issue: 28
Pages: 3124-3129
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.7401
OpenAlex: W2161479848
Cited by: 398
References: 39
Citations by year: 2026: 18 · 2025: 19 · 2024: 23 · 2023: 40 · 2022: 40 · 2021: 71 · 2020: 50 · 2019: 27 · 2018: 42 · 2017: 30 · 2016: 26 · 2015: 12
FWCI: 25.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Canadian Cancer Society Research Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: germline BRCA1 mutation, germline BRCA2 mutation, pancreatic ductal adenocarcinoma, family history of cancer, Ashkenazi Jewish ancestry, hereditary cancer predisposition
MeSH terms: Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Female, Gene Frequency, Humans, Jews, Male, Middle Aged, Ontario, Pancreatic Neoplasms, Pedigree, Phenotype, Prognosis, Prospective Studies, Risk Factors, Incidence, Germ-Line Mutation, BRCA1 Protein, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, BRCA2 Protein, Heredity, Multiplex Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks